The removal of chlorofluorocarbon (CFC) propellants from industrial and household products has been agreed to by over 165 countires of which more than 135 are developing countries. The timetable for this process is outlined in the Montreal Protocol on Substances that Deplete the Ozone Layer document and in several subsequent amendments. Pressured metered dose inhalers (pMDIs) for medical use have been granted temporary exemptions until replacement formulations, providing the same medication via the same route, and with the same efficacy and safety profiles, are approved for human use. Hydrofluoroalkanes (HFAs) are the alternative propellants for CFCs-12 and -114. Their potential for damage to the ozone layer is nonexistent, and while they are greenhouse gases, their global warming potential is a fraction (one-tenth) of that of CFCs. Replacement formulations for almost all inhalant respiratory medications have been or are being produced and tested; in Canada, it is anticipated that the transition to these HFA or CFC-free pMDIs will be complete by the year 2005. Initially, an HFA pMDI was to be equivalent to the CFC pMDI being replaced, in terms of aerosol properties and effective clinical dose. However, this will not necessarily be the situation, particularly for some corticosteroid products. Currently, only one CFC-free formulation is available in Canada -Airomir, a HFA salbutamol pMDI. This paper discusses the in vitro aerosol characteristics, in vivo deposition and clinical data for several HFA pMDIs for which there are data available in the literature. Alternative delivery systems to the pMDI, namely, dry powder inhalers and nebulizers, are briefly reviewed. sont des gaz à effet de serre, leur potentiel global de réchauffement repré-sente une fraction (un dixième) de celui des CFC. Des formules de substitution pour presque tous les médicaments respiratoires administrés par inhalation ont été et sont testées. Au Canada, on espère que la transition vers ces aérosols-doseurs générés aux HFA ou ne contenant pas de CFC sera terminée vers 2005. Initialement, un aérosol-doseur généré par HFA devait être équivalent à l'aéro-sol-doseur généré par CFC que l'on remplaçait, relativement aux propriétés de l'aérosol et à la dose clinique efficace. Cependant, ce ne sera pas nécessairement le cas, en particulier pour certains produits contenant des corticostéroïdes. Actuellement, une seule formulation sans CFC est disponible au Canada -Airomir, un aérosol-doseur contenant du salbutamol et généré par HFA. Le présent article discute des caractéristiques de l'aérosol in vitro et du dépôt in vivo, et des données cliniques obtenues sur plusieurs aérosols-doseurs générés par HFA et sur lesquels des données sont disponibles dans la littérature. L'alternative aux aérosols-doseurs, à savoir, les inhalateurs à poudre sèche et les nébuliseurs, sont brièvement passés en revue.
I n 1987, 140 countries signed the final draft of the Montreal Protocol on Substances that Deplete the Ozone Layer, the document that outlined the procedures and timetable to be followed for phasing out the use of chlorofluorocarbon (CFC) propellants in industry. Exemptions are made yearly for essential uses of CFCs, and the medical use of CFCs in pressurized metered dose inhalers (pMDIs) for the treatment of asthma and chronic obstructive pulmonary diseases falls into this category. Applications to use CFCs must be negotiated yearly for use in two years and should be viewed as temporary extensions of the projected time to complete elimination because allowances may not be granted after the year 2005. In Canada, the criteria that must be met before phasing-out of CFC propellants in pMDIs have been outlined in the Canadian Initial Transition Strategy for the Phase-Out of Chlorofluorocarbon (CFC) use in Metered Dose Inhalers (MDIs) draft document from Health Canada and Environment Canada, developed after consultation with representatives from medical and allied health professional organizations, patient information groups, environmental groups, the pharmaceutical industry and various government departments. This initial document has been circulated (1) but is not yet finalized.
CFC PHASE-OUT OBJECTIVES
In Canada, the majority opinion of those consulted favoured adopting a transition policy based on a drug-by-drug removal protocol rather than the phase-out of a specific drug category. Thus, as a particular CFC-free pMDI is approved for use, the CFC pMDI is removed from the provincial formularies, but only after a reasonable period of time during which both products are available for therapy. Before the removal of a specific drug and the transition to the replacement formulation can occur, sufficient quantities of the alternative drug must be available from the pharmaceutical companies, as well as sufficient types of alternatives to meet the needs of different patient groups. At least 12 and possibly 18 months of postmarketing surveillance data must also be obtained to confirm the (long term) safety of replacement formulations.
One of the main goals of the Canadian Initial Transition Strategy is to reduce the need for CFC pMDI use by 60% by the year 2001 and to achieve complete phase-out by the year 2005. Most respiratory medications are also available in Canada as products dispensed via the other two major categories of aerosol delivery systems, ie, dry powder inhalers (DPIs) and nebulizers ( Figure 1 ). Only two drugs are available solely as DPIs, Bricanyl Turbuhaler (Astra Pharma, Mississauga, Ontario) and Foradil (Novartis, Dorval, Quebec). Data available for 1996 usage indicate that CFC pMDIs accounted for 79% of the perscriptions for aerosol drug delivery systems, DPIs 13% and nebulizers 8% (2) . In Canada, there are 18 approved active ingredients used to treat respiratory diseases by inhalation. Approximately 11 million pMDIs inhalers were sold across the country in 1996, and, of these, 57.5% were beta-agonists, predominantly salbutamol sulphate (55.4% or 5,900,334 units). Inhaled corticosteroids accounted for a further 25.8% of the total, with beclomethasone dipropionate (BDP) comprising 21.9% or 2,329,793 units. A possible way of achieving the 2001 target could be to remove CFC salbutamol from the market, because there are alternative delivery systems in place (Figure 1 ).
CFC AND HFAs: ENVIRONMENTAL CONCERNS
CFCs are nontoxic, stable chemicals containing carbon, chlorine and fluorine (Table 1) . Originally manufactured for industrial uses, mainly refrigeration and foam insulation products, their advantage as the energy source for producing pharmaceutical aerosols was recognized in the mid-1950s. The medical use of CFCs has accounted for less than 1% of the total production of CFCs; however, with the elimination of CFCs for industrial uses and in household products, this percentage has increased, with parallel increases in the cost of production for this limited medical market.
The observation that CFCs cause atmospheric ozone depletion was made by Molina and Rowland in 1974 (3) . The resulting long term environmental and health effects of CFCs are a major global concern and caused a limited ban on the nonmedical use of CFCs to be enforced in several countries in the late 1970s. The Vienna Convention was drawn up in 1985, culminating in the Montreal Protocol in 1987. Three amendments to the protocol have been made that have accelerated the original time frame for the complete removal of CFCs (4) .
The replacement propellants, hydrofluroalkanes (HFAs) -134a and -227 have physicochemical properties similar to the three CFCs that are used in medical inhalers (Table 1) New delivery systems and propellants
Figure 1) Packaging of inhalant therapies in Canada for the three main categories of aerosol delivery systems. CFC Chlorofluorocarbon; DPI Dry powder inhaler; pMDI Pressured metered dose inhaler
ties, coupled with the lack of compatible surfactants for these replacement propellant fomulations necessitating changes to the hardware (canister valves and seals), have resulted in different aerosol characteristics for some inhalers.
HFA pMDIs Very few widely used CFC pMDIs are not being reformulated as HFA pMDIs. The formulations in development are to be the same as the current CFC product in terms of nominal dose per actuation and particle size characteristics. This has proven mostly true for beta-agonists under development, but is not universal for HFA steroids. Because corticosteroids are readily soluble in ethanol and, hence, are then dissolved in the replacement propellant, HFA-134a, some of these formulations have become solutions rather than suspensions. In some instances, the steroid sprays are finer than the CFCs, but because there are limited published data, this may not be true for all steroid HFA inhalers. In Canada, there is currently only one approved replacement propellant pMDI, namely, Airomir (3M Pharmaceutials, London, Ontario), a HFA-134a salbutamol sulphate inhaler. HFA salbutamol: Table 2 lists the ingredients for CFC Ventolin pMDI (Glaxo Wellcome, Mississauga, Ontario) compared with Airomir. The composition of the HFA formulation is different, requiring salbutamol sulphate as the active ingredient rather than salbutamol. However, the quantities have been adjusted to deliver 100 mg of salbutamol per actuation. In addition, Airomir contains a small quantity of ethanol, but it is not sufficient to alter the particle size of this replacement formulation. There are differences, however, in the physical properties of the spray compared with CFC Ventolin. The spray temperature is above freezing (+14°C versus -2°C) (5) , and the jetting force of the spray is much reduced (2.4 milliNewtons versus 6.2 milliNewtons) (6). The warmer spray should alleviate the cold Freon effect that many patients experience on taking their CFC MDIs, particularly children, and the reduction in the spray velocity should reduce the oropharyngeal dose. Compared with CFC salbutamol, the HFA pMDI spray looks different mainly because of the reduced jetting velocity, sounds different for the same reason, and tastes different, largely due to the ethanol, which has recently been reported to cause a transient increase in breath alcohol levels (7). Clinically, the effects and incidence of side effects are similar as has been demonstrated in a number of clinical trials (8) (9) (10) (11) .
Reformulation plus the hardware improvements have also resulted in better canister performance. Compared with CFC pMDIs, there is no reduction in the dose per actuation when the inhaler is not used for several hours, an effect extending up to two weeks. The emitted dose per actuation is consistent through the life of the canister, ie, there is no tail-off of drug available when the canister is almost empty, and there is no reduction in the emitted dose at ambient temperatures as low as -20°C. Thus, in the winter, asthmatics should not receive less drug per puff if the HFA canister is left in the car or carried in a purse or briefcase, for example.
The particle size distribution of Airomir versus Ventolin has been shown to be the same (Figure 2) (12,13) . The mass median aerodynamic diameter of Airomir is 2.69 µm versus 2.62 µm for Ventolin, but the fine particle fraction of the emitted dose as inhaled into the lung contained in particles less than 5.8 µm in diameter was greater for Airomir (65.5% versus 41.4%, P<0.05) (13, 14) . The emitted doses are different, being less for Airomir than Ventolin (85.3±5.4 µg versus 96.9±6.9 µg, p.05) (13), but, because the fine particle fraction is greater for Airomir, this translates into a fine particle dose for Airomir of 54.2 µg compared with that of 40.3 µg for Ventolin. When Airomir was used with several spacers of different volumes, the fine particle dose was enhanced and comparable between all spacers: approximately 70 µg was measured at the mouthpiece of the Aerochamber (Trudell Medical International, London, Ontario) or Babyhaler (Glaxo Wellcome, Ware, United Kingdom) or metal Nebuchamber (Astra Pharma, Lund, Sweden) (13, 14) . A series of pharmcokinetic studies in normal subjects from Lipworth and co-workers (15) levels with HFA salbutamol inhaled through both plastic and metal spacers compared with either the HFA pMDI alone or salbutamol delivered through the Turbuhaler (16), supporting greater total deposition in the lung of HFA salbutamol. HFA steroids: Transition to HFA pMDI aerosols has, by necessity, produced different formulations for some existing drugs, resulting in aerosols with particle size characteristics which are not the same as the CFC products that they are replacing. Beclomethasone diproprionate (BDP) is one such example. QVAR (3M Pharmaceuticals, St Paul, Minnesota) is the CFC-free formulation that is expected to be approved shortly in Canada. Its aerosol characteristics are quite different to the existing CFC BDP (Beclovent, Glaxo Wellcome, Ware, United Kingdom) owing to the changes in the formulation. Without a compatible surfactant, BDP, of necessity, is dissolved in ethanol to make it soluble in the propellant (HFA-134a). Thus, the formulation produces a solution rather than the suspension aerosol as with the CFC pMDI (12) . As with Airomir, the temperature of the QVAR spray is above freezing and the spray velocity reduced (6) . Stability of the emitted dose with short term storage and tail-off effects are similar to Airomir. The results for emitted dose and particle size measurements for QVAR and Beclovent are given in Table 3 . Emitted doses are the same for both formulations, but QVAR is a much finer aerosol, with all of the emitted dose well within the respirable range. Radiolabelled deposition studies comparing QVAR with CFC Beclovent have shown a 10-fold increase in lung deposition of the HFA BDP (Table 4) (12, 17) . In addition, the oropharyngeal deposition from a QVAR puff is reduced by approximately one-third and further decreased with the use of the Aerochamber (Table 5) . Because of the particle size characteristics of the aerosol, approximately 10% of the dose will be exhaled (12) , even with a breath-hold.
Values are given in Table 4 for one other reformulated steroid for which there are published data, namely HFA flunisolide (Aerobid, Forest Labs, New York, New York); this also shows a trend towards increased deposition compared with the CFC pMDI in the control subjects studied and patients with asthma (18) . Both products are solutions, which may explain this similarity. Lung deposition for the HFA flunisolide was enhanced and oropharyngeal deposition reduced with the addition of a valved spacer (Table 5) , again confirming that these devices are of benefit when used with the replacement propellant pMDIs. Pharmacokinetic studies only have been performed with CFC versus HFA-134a fluticasone (Flovent, Glaxo Wellcome, United Kingdom) and indicate similar systemic bioavailability (19) .
A number of dose comparison studies between Beclovent and QVAR have indicated that a 2.5-fold reduction in the prescribed dose of QVAR will give similar efficacy to Beclovent, with the same safety profile (20) .
ALTERNATIVE DELIVERY SYSTEMS
The need to eliminate CFC-containing pMDIs has provided the impetus to develop new, non-CFC dependent aero- The criteria for removal of an existing CFC pMDI are also governed by the availability of these alternative delivery systems. These systems must provide the active drug substance via the same route ie, the inhaled route. Furthermore, the drug in the alternative device must be approved for the same clinical indication as the CFC pMDI, be as safe and have the same side effect profile as the CFC formulation, and provide approximately the same level of convenience for the patient. Apart from producing an innovative, cost effective design for each of these types of products, the need to demonstrate appropriate aerosol characteristics for inhalation into the lower respiratory tract, reproducibility in delivered dose of the active ingredient, and efficacy and safety comparable with the existing (CFC pMDI) product guarantees a time line of approximately five to 10 years from concept to market. Despite this huge investment of time and money by the pharmaceutical industry and the device manufacturers, dry powder inhalers and nebulizers should be viable alternatives to the CFC pMDI for a large segment of the patient population. It is anticipated that many of these new systems will be available well before the year 2005. However, young children and infants, patients in the intensive care unit and the elderly still need HFA pMDIs with holding chambers for effective therapy. Dry powder inhalers: In the past few years, two new DPI designs have been approved for use in Canada with salmeterol xinafoate, fluticasone propionate and formoterol. A recent survey of patent applications and the literature suggests that there are approximately 10 to 20 devices in various stages of development in North America and Europe. Table 6 shows the range of lung deposition values for some of these inhalers. The studies were performed mostly in normal subjects and at the manufacturer's suggested inspiratory flowrate for optimal performance. Deposition values vary three- fold between these DPIs, but are still approximately half the value published for QVAR (17) . Oropharyngeal doses (not shown) are about 60% for all the DPIs shown. Of these systems, all but the Spiros (Dura Pharmaceuticals, San Diego, California) (not yet available in North America) and the Diskus (Glaxo Wellcome, Mississauga, Ontario) store the drug powder in a bulk reservoir. These two DPIs are examples of innovative multiunit dose systems that provide 60 to 80 individual doses of drug in either a rotating cassette (Spiros) or a coiled tape (Diskus). As with the pMDIs, all the devices listed give the patient the convenience of a one month's supply of drug in one inhaler.
CONCLUSIONS
The transition to HFA pMDI formulations of existing CFC pMDIs is proceeding in developed countries. There may be recognizable differences with some CFC-free pMDIs and potential advantages in delivery to the lung with others, the latter resulting from the reformulation process and improved canister hardware. Patients, physicians and healthcare professionals need to be made aware of the greater health issues necessitating the change, and that while the environmental benefits of reducing the CFC burden will not be evident for some years, the effects will be much more severe if not begun now. It should be stressed that the replacement pMDIs are as efficacious as the CFC ones and that the costs to the patient are currently the same as for the CFC pMDIs. Assurances must also be given to patients and physicians that, while transition is happening now, the removal of an existing CFC pMDI from the market will not occur until there are sufficient data and experience with the HFA replacement.
